PAVmed Inc. (PAVM)
CIK 1624326 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 7.3M shares as of May 12, 2026 (10-Q). Share count fell from 120.8M to 9.2M between Nov 9, 2023 and Mar 21, 2024, a pattern consistent with a reverse split (roughly 1-for-13); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Veris Warrants | 1.8M | not tagged | — | — |
| Lucid Rights | 300,000 | not tagged | — | FV $375,000 |
| Right | 300,000 | not tagged | — | — |
| Series D Preferred Stock Warrant | 30,000 | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed May 14, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 756,734 underlying shares, as reported Feb 18, 2025 (10-Q).
Reported exercise price: $0.7115 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $11.7M as of Feb 3, 2026.
Rough fully diluted estimate: 8.0M = 7.3M O/S + 756,734 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Owed To Pavmed | not tagged | $24.0M | $1.5 | — | — |
| the 2026 Note | $15.0M | $15.0M | $450 | 15% | ~33,333 sh |
| September 2022 Senior Convertible Note | $7.8M | $11.3M | $32.04 | 7.875% | ~244,663 sh |
If every note above converted at its tagged price: ~277,996 new shares on 7.3M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed May 14, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 7.3M | May 12, 2026 |
| + Veris Warrants (if exercised) | 1.8M | Jun 23, 2025 |
| + Lucid Rights (if exercised) | 300,000 | Feb 3, 2026 |
| + Right (if exercised) | 300,000 | Feb 3, 2026 |
| + Series D Preferred Stock Warrant (if exercised) | 30,000 | Feb 3, 2026 |
| + the 2026 Note (if fully converted) | 33,333 | Mar 31, 2026 |
| + September 2022 Senior Convertible Note (if fully converted) | 244,663 | Dec 31, 2025 |
| Fully diluted estimate | 10.0M | +37.2% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Registered offering capacity on live registrations: $84.8Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted
Last 12 months: 1 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full PAVM workspace